ATLAS ACS-2, TIMI 51

Posted by on

Rivaroxaban in Patients with Recent Acute Coronary Syndrome - The New England Journal of Medicine - 2012

Brief Summary:

In patients with recent ACS, the addition of rivaroxaban to standard dual antiplatelet therapy reduced the composite of CV mortality, recurrent MI, or stroke, but increased the risk of nonfatal bleeding.

Reference:
http://www.ncbi.nlm.nih.gov/pubmed/22077192


Comments

Post a Comment

Drop your thoughts here, we would love to hear from you